Related Experiment Video

Updated: Jun 8, 2025

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.2K

Oncogenic EML4-ALK assemblies suppress growth factor perception and modulate drug tolerance

David Gonzalez-Martinez1, Lee Roth1, Thomas R Mumford1

  • 1Department of Bioengineering, University of Pennsylvania, Philadelphia, PA, 19104, USA.

Nature Communications
|November 3, 2024
PubMed

Insights

Drug resistance in ALK-driven cancers is linked to EML4-ALK protein assemblies. These assemblies suppress receptor tyrosine kinase (RTK) signaling, but ALK inhibition unexpectedly resensitizes RTKs, promoting cell survival via ERK reactivation.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • Drug resistance is a major hurdle in treating cancers driven by EML4-ALK fusion oncogenes.
  • EML4-ALK forms cytoplasmic protein condensates, but their role in drug response is not fully understood.

Purpose of the Study:

  • To investigate the function of EML4-ALK assemblies in targeted therapy response.
  • To elucidate the mechanism of drug resistance and identify potential therapeutic strategies.

Main Methods:

  • Utilized optogenetics and live-cell imaging to study EML4-ALK assemblies.
  • Analyzed the interaction between EML4-ALK, adapter proteins, and receptor tyrosine kinase (RTK) signaling pathways.

Main Results:

  • EML4-ALK assemblies suppress RTK signaling by sequestering adapter proteins like GRB2 and SOS1.
  • ALK inhibition releases these adapters, resensitizing RTK signaling and leading to pulsatile ERK reactivation.
  • Reactivated ERK signaling, driven by paracrine ligands from dying cells, promotes cancer cell survival.

Conclusions:

  • EML4-ALK assemblies play a regulatory role in RTK signaling and drug response.
  • A novel mechanism of tolerance to targeted therapies involving RTK resensitization and ERK reactivation has been uncovered.
  • Combination therapies targeting paracrine signaling alongside ALK inhibition may overcome drug resistance.

More Related Videos

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

3.9K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.8K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
4.7K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K